Novartis Sues Ranbaxy Over Top-Selling Diovan
Novartis International AG has sued Ranbaxy Laboratories Limited, looking to stave off generic competition in the multibillion dollar market for the hypertension treatment Diovan, which Novartis touts as the world's leading...To view the full article, register now.
Already a subscriber? Click here to view full article